Core Insights - Autonomix Medical, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, showcasing its commitment to advancing precision nerve-targeted treatments [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [4] Technology Development - Initial development of the technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]

Core Insights - Autonomix Medical, Inc. is expanding its clinical trials to include additional visceral cancer indications, effectively doubling its potential addressable market beyond pancreatic cancer pain [1][2] - The initiation of the PoC 2 phase follows positive results from the PoC 1 trial, which focused on patients with severe pancreatic cancer pain, indicating a strong foundation for multi-indication growth [2][3] - The company's technology platform has the potential to address a wide range of medical conditions, including cardiology, hypertension, and chronic pain management, with a concentrated focus on interventional cancer pain management applications [3][5] Company Overview - Autonomix Medical, Inc. is dedicated to advancing innovative technologies for diagnosing and treating diseases related to the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4][5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]

Core Insights - Autonomix Medical, Inc. has received Ethics Committee authorization to expand its clinical trials for a proprietary ablation technology aimed at treating visceral cancer pain, building on initial success in pancreatic cancer pain [2][3] - The follow-on phase of the clinical program (PoC 2) is set to begin patient enrollment in June 2025, with the potential to double the addressable market by including additional visceral cancers [2][3][4] Group 1: Clinical Development - The PoC 2 phase will evaluate the safety and effectiveness of delivering transvascular energy to ablate problematic nerves, with a focus on interventional cancer pain management applications [2][4] - Initial trials in late-stage pancreatic cancer patients showed promising results, including significant pain reduction and decreased opioid use, indicating the technology's potential to transform cancer pain management [3][4] Group 2: Market Expansion - The expansion into visceral cancer pain aligns with Autonomix's strategy to create long-term value through multi-indication growth, addressing significant unmet needs in cancer treatment [3][4] - The technology platform has the potential to address various indications beyond cancer, including cardiology and chronic pain management, indicating a broad market opportunity [4][6][7] Group 3: Technology Overview - Autonomix's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [6][7] - The investigational nature of the technology means it has not yet been cleared for marketing in the United States, highlighting its developmental stage [7]

Core Insights - Autonomix Medical, Inc. is set to initiate a follow-on phase ("PoC 2") of its proof-of-concept trial, focusing on the safety and effectiveness of transvascular energy delivery to alleviate cancer pain, with the expansion phase expected to start in Q2 2025 [2][3][4] Company Overview - Autonomix is a medical device company dedicated to advancing innovative technologies for diagnosing and treating diseases related to the nervous system [7][8] - The company's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [7] Market Expansion - The follow-on PoC 2 phase aims to evaluate additional visceral cancers, potentially doubling the addressable market beyond pancreatic cancer pain, by including gall bladder, liver, and bile duct cancers [3][4] - The initial phase (PoC 1) demonstrated significant pain reduction and decreased opioid use in patients with severe pancreatic cancer pain, leading to the decision to expand the investigation [4][5] Technology and Applications - Autonomix's technology is positioned as a platform capable of addressing various indications, including cardiology, hypertension, and chronic pain management, with a concentrated focus on interventional cancer pain management applications [5][8] - The company has established key opinion leader relationships and emerging preclinical evidence to support further expansion in oncology and gastroenterology sectors [5]